Theraclion SA · EURONEXT:ALTHE
Theraclion SA — Investor Presentation (May 2025)
33 slides from Theraclion SA's investor presentation, May 19, 2025
Slide 1: Investor Presentation: Disrupting the Varicose Vein Market with SONOVEIN
INVESTOR PRESENTATION DISRUPTING THE VARICOSE VEIN MARKET WITH SONOVEIN® May 2025
Slide 2: Executive Summary
EXECUTIVE SUMMARY • A disruptive approach to varicose vein treatment: SONOVEIN® is totally non invasive and robotic driven • Huge market: varicose veins affect 1 in 3 adults, 13 B$ total market • Proven technology: 90% to 100% efficacy*, zero serious adverse event, 3 000+ veins treated, commercial P
Slide 3: Market Overview
Market Overview
Slide 4: Varicose Veins: A Widespread Condition
VARICOSE VEINS: A WIDESPREAD CONDITION WHAT ARE VARICOSE VEINS? Varicose veins are swollen, twisted subcutaneous veins of the lower leg THE VENOUS SYSTEM Superficial Defective of the valves results in compartment Cosmetic impact reflux of blood in the veins Saphenous Incompetent saphenous veins ofte
Slide 5: A Disruptive Treatment for Varicose Veins
A DISRUPTIVE TREATMENT FOR VARICOSE VEINS Two main current methods… STRIPPING ENDOVENOUS INVASIVE ++ INVASIVE + NON INVASIVE ROBOTIC NO SURGERY DRIVEN VERY LOW RISK Surgery* Laser, Radiofrequency, Glue** • No serious adverse event to date • Robotic driven, live US monitoring • Quick walk-in walk-out
Slide 6: Varicose Veins: A Multibillion $ Market Potential
VARICOSE VEINS: A MULTIBILLION $ MARKET POTENTIAL ALIGNED WITH CURRENT MARKET TRENDS $13B • 6,5% annual growth in varicose veins Current medical costs for varicose vein patients driven by treatments worldwide Age Obesity Lifestyle 54% of undiagnosed patients in 5M+ • industrialized countries Annual
Slide 7: SONOVEIN Value Creation for Medical Devices in a Multibillion $ Market
SONOVEIN VALUE CREATION FOR MEDICAL DEVICES IN A MULTIBILLION $ MARKET POTENTIAL Surgical stripping Endovenous SONOVEIN Peripherals Med. Device Peripherals Med. Device Peripherals Med. Device costs cost costs cost costs cost Minimally Non invasive invasive Medical device 1-2% revolution 10-20% revol
Slide 8: SONOVEIN: A game-changing technology
SONOVEIN® A game-changing technology
Slide 9: SONOVEIN, a Non-Invasive Robotic Solution
SONOVEIN®, A NON-INVASIVE ROBOTIC SOLUTION 1 Robotic treatment head 1 Robotized head with embedded ultra-sound imaging 2 Touchscreen 4 Robotized 3 Treatment head 3 head 4 Rear handle and brakes 2 7 Consumable: 5 Front connection panel Cooling and coupling 5 Technology (through 6 Ultrasound probe Epa
Slide 10: SONOVEIN, a Non-Invasive Robotic Solution (HIFU)
SONOVEIN®, A NON-INVASIVE ROBOTIC SOLUTION High IntensityFocusedUltrasound(HIFU) Waves Imaging Array HIFU transducer Skin Incompetentvein Leg tissue Ultrasound waves Venous target The energy is delivered via the extra-corporeal treatment probe. The high-energy ultrasound waves propagate through the
Slide 11: A Simple and Quick Workflow
SONOVEIN®, A NON-INVASIVE ROBOTIC SOLUTION A simple and quick workflow Typical treatment 45-60 minutes Step 1. Preparation 2. Treatment 3. Wrap-up ▪ Treatment head positioning ▪ Room preparation ▪ Post-treatment ▪ Automatic skin detection ▪ Device set up ▪ Vein detection imaging Description ▪ Power
Slide 12: SONOVEIN: The Swiss Knife of Vein Treatment
SONOVEIN: THE SWISS KNIFE OF VEIN TREATMENT PRODUCT VERSATILITY DRIVING VALUE AND MARKET PENETRATION Perforators Stumps Tortuous veins difficult to catheterize SONOVEIN 01 Key treatment advantages Ulcers: treatment of perforators (or other veins) 02 below damaged skin not allowing percutaneous acces
Slide 13: SONOVEIN: A product ready for scale-up
SONOVEIN® A product ready for scale-up
Slide 14: SONOVEIN, Now a Mature Device
SONOVEIN®, NOW A MATURE DEVICE EFFECTIVE AND SAFE TREATMENT OF VARICOSE VEINS OVER 3,000 VEIN TREATMENTS TO DATE • 90% to 100% efficacy* • 0 severe adverse event** • Treatment duration ≤1h ESTABLISHED INTERNATIONAL PRESENCE • Commercial sites in 10+ countries • Presence in EU, Middle East, Asia, US
Slide 15: Selected Publications and Congress Presentations
SONOVEIN®, NOW A MATURE DEVICE EFFECTIVE AND SAFE TREATMENT OF VARICOSE VEINS Selected publications and congress presentations with 90% to 100% efficacy, on 6+ sites across Europe, across hundreds of patients, up to 3-year follow-up, in commercial routine TYPE OF RESULT AUTHOR EFFICACY RESULTS TITLE
Slide 16: R&D as a Market Penetration Driver
SONOVEIN®, NOW A MATURE DEVICE R&D AS A MARKET PENETRATION DRIVER 2019 2020-21 2022-23 2023-24 2025-26 AI, ACOUSTICS SONOVEIN SONOVEIN S SONOVEIN S+ SONOVEIN 3D ROBOTICS and HD HD23 (target) MAIN FOCUS: R&D, Product Development COMMERCIAL ACCELERATION INCREASING MARKET PENETRATION 2h TREATMENT DURAT
Slide 17: R&D as a Market Penetration Driver
R&D AS A MARKET PENETRATION DRIVER IMPROVING THE PRODUCT TO ENLARGE ADDRESSABLE PATIENTS & CENTERS From: 45 min to 1h ACCELERATE TREATMENT TIME Down to: 30min From: a device for an ultrasound IMPROVE trained medical doctor EASE OF USE Down to: an AI-guided, intuitive device for a non-specialist From
Slide 18: Why AI Is the Future of SONOVEIN
R&D AS A MARKET PENETRATION DRIVER WHY AI IS THE FUTURE OF SONOVEIN Live imaging + robotics + AI engine => road to automated treatment 1 The SONOVEIN is permanently collecting US imaging and technical data User US images => an integrated AI engine (GPU) could analyse and propose treatment action: fe
Slide 19: SONOVEIN: Go-to-Market strategy
SONOVEIN® Go-to-Market strategy
Slide 20: Go to Market Acceleration: Two Business Models
GO TO MARKET ACCELERATION TWO BUSINESS MODELS FAVORING RECURRING REVENUES PAY-PER-USE DIRECT SALES Paying per Capital equipment consumables, + all inclusive Consumables + (w/ monthly min. quantity) Service OUR CONSUMABLE Single-use EPack : Europe & USA China, Middle East & R.o.W. ensures cooling and
Slide 21: US Market: A Main Priority
US MARKET: A MAIN PRIORITY FDA STUDY TREATMENTS COMPLETED 2022 2023 2024 2025 2026 2027 onwards Feasibility Pivotal Study Final Treatments Final Results Expected FDA Reimbursement study starts (Mid 2024) (Mid 2025) Clearance, successful Partnerships 1,000 35% 1,300 450k+ Addressable sites Target mar
Slide 22: EU Market: A Commercial Potential and Partnerships Developments
EU MARKET: A COMMERCIAL POTENTIAL AND PARTNERSHIPS DEVELOPMENTS 1,500 35% 600 315k+ Addressable sites Target market share no. treatments per site Sonovein treatments (yearly. avg) COMMERCIAL RAMP-UP PRODUCT REFINEMENT WITH KOL INTERNATIONAL • Tier-1 sites at 100 or 150 • Fine-tuning product, protoco
Slide 23: Opportunities in China and Rest of the World
OPPORTUNITIES IN CHINA AND REST OF THE WORLD MARKET MARKET • Largest potential varicose vein market in Asia • Inbound demand from some countries, • Underserved market that could move directly to especially Middle East Sonovein’s non-invasive solution to reach so far • Business Model: Sonovein acquis
Slide 24: Growth Roadmap and Key Milestones
GROWTH ROADMAP AND KEY MILESTONES 2031 2028+ 2027 Global 2026 expansion 2025 Ability Worldwide leader 2024 to scale up Ramp-up Established Minimum viable product in Europe Pivotal study Pivotal study final FDA Clearance/ US Salesforce Reimbursement USA treatments Strategic results completed Partners
Slide 25: SONOVEIN: A foundation for future perspectives
SONOVEIN® A foundation for future perspectives
Slide 26: SONOVEIN Success Will Open the Way to Other Therapies
SONOVEIN SUCCESS IN VARICOSE VEINS WILL OPEN THE WAY TO OTHER THERAPIES MORE INDICATIONS Hyperthermia - Possibility BREAST CANCER to heat cancer tissue locally prior to radiotherapy $20B market, strong growth THYROID NODULES Research programs ongoing Huge potential for HIFU $3.6B market combined wit
Slide 27: THERACLION: Structured for Success
THERACLION Structured for Success
Slide 28: A Sharp and Engaged Management Team
A SHARP AND ENGAGED MANAGEMENT TEAM A DYNAMIC … SUPPORTED BY A HIGHLY SKILLED AND EXPERIENCED TEAM LEADERSHIP Christophe Lamboeuf Marie Berne Michel Nuta, MD Jérémie Anquez, PhD Chief Financial Officer Head of Marketing & Chief Medical Officer Chief Scientific Officer 30+y. exp, Mauna Kea, Customer
Slide 29: An Experienced and Supportive Board
AN EXPERIENCED AND SUPPORTIVE BOARD AN EXPERIENCED WITH HIGHLY QUALIFIED BOARD MEMBERS CHAIRMAN Lijuan Deng Ari S. Kellen, MD Shawn Langer, MD Board Member Board Member Board Member 17+y. in healthtech US-based, Ex. McKinsey, US-based, Ex. senior partner Board of Echosens, Furui Experienced operatin
Slide 30: Theraclion Shareholding Structure
THERACLION SHAREHOLDING STRUCTURE SHAREHOLDERS FURUI (300049:CH): GENUINE STRATEGIC (as of December 31st, 2024) PARTNERSHIP Furui • Theraclion’s investor since 2016 28,9% Concert Bernard • China JV created in 2017 Sabrier 29,9% Management • Replication of Echosens’ Success: Opus Chartered • Echosens
Slide 31: Glossary
GLOSSARY • HIFU: High Intensity Focused Ultrasound is a non-invasive therapeutic technique that uses non-ionizing ultrasonic waves to heat or ablate tissue. • Venous reflux or Chronic Venous Insufficiency (CVI): occurs when veins no longer circulate blood properly. It often affects the leg veins, ca
Slide 32: Disclaimer
DISCLAIMER This presentation does not constitute an offer to sell or a solicitation of a THERACLION share purchase offer. Some information in this document may include projections and forecasts. THERACLION believes that these forward-looking statements are based on reasonable assumptions as at the d
Slide 33: Thank you!
Thank you! FOLLOW US ON LINKEDIN FOR UPDATES bit.ly/3KYQKJD THERACLION 244 av. Pierre Brossolette 92240 Malakoff T +33 1 55 48 90 70 E contact@theraclion.com